GlassScriptPhysician profile
Rajendra P Koirala
NPI 1952588972
$12,069.47
in general payments reported to CMS, 2019-2025
35 companies · $1,890 in 2025
The $1,890 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,094 · 2020: $894 · 2021: $2,357 · 2022: $1,454 · 2023: $1,886 · 2024: $2,494 · 2025: $1,890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,176 · Education: $93.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,175.91 |
| Education | $93.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,647.57 | 2021-2025 | |
| Lundbeck LLC | $1,309.91 | 2019-2025 | Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $1,171.27 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $979.04 | 2020-2025 | Caplyta |
| Neuronetics, INC. | $961.74 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $931.41 | 2020-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $853.76 | 2022-2025 | Spravato |
| Alkermes, INC. | $841.99 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Takeda Pharmaceuticals U.S.A., INC. | $620.45 | 2019-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $473.09 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $453.72 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $415.10 | 2023-2025 | Auvelity |
| Allergan, INC. | $404.09 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $124.45 | 2019 | |
| Corium, LLC | $107.03 | 2023-2024 | Azstarys |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $82.89 | 2019-2023 | Zubsolv |
| Alfasigma USA, INC. | $73.91 | 2022 | |
| Almatica Pharma LLC | $70.79 | 2024 | Loreev Xr |
| Jazz Pharmaceuticals INC. | $64.93 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $60.31 | 2025 | |
| Sage Therapeutics, LLC | $57.82 | 2024-2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $54.35 | 2022-2023 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $46.55 | 2021-2024 | Uzedy |
| Validus Pharmaceuticals LLC | $33.72 | 2023 | Equetro |
| Tris Pharma INC | $30.45 | 2024-2025 | Dyanavel Xr |
| Hikma Pharmaceuticals USA | $29.74 | 2021-2022 | |
| Noven Therapeutics, LLC | $29.52 | 2022 | |
| Avanir Pharmaceuticals, INC. | $26.42 | 2019-2020 | |
| Inspire Medical Systems, INC. | $24.78 | 2025 | Inspire |
| Braeburn INC. | $17.96 | 2024 | Brixadi |
| Shire North American Group INC | $17.94 | 2019 | |
| Indivior INC. | $14.99 | 2024 | Sublocade |
| Tempus Ai, INC | $13.33 | 2024 | |
| Idorsia Pharmaceuticals US INC | $12.31 | 2022 | |
| Eisai INC. | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajendra Koirala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.